Correcetions to “A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)”-Reference-Cited by-同舟云学术

Correcetions to “A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)”

Published:2017-11 Issue:11 Volume:28 Page:2901-2905
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cherny N.I.,Sullivan R.,Dafni U.,Kerst J.M.,Sobrero A.,Zielinski C.,de Vries E.G.E.,Piccart M.J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/doi/10.1093/annonc/mdw258/11043902/mdw258.pdf

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update;Journal of Clinical Oncology;2024-09-11

2. Documenting the Full Value of Vaccination: A Systematic Review of Value Frameworks;Value in Health;2024-09

3. Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study);Lung Cancer;2024-07

4. Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials;BMJ Open;2024-06

5. Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending;BMJ Oncology;2024-01